Tourette Syndrome (TS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Tourette Syndrome (TS) Market Outlook

Thelansis's "Tourette Syndrome (TS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Tourette Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Tourette Syndrome (TS) Overview

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by the presence of multiple motor tics and at least one vocal (phonic) tic persisting for more than one year, with onset before 18 years of age. The condition is associated with dysfunction in the cortico-striato-thalamo-cortical (CSTC) circuitry, primarily driven by dopamine dysregulation.

TS belongs to the spectrum of tic disorders, which also includes Provisional Tic Disorder and Persistent Motor or Vocal Tic Disorder. Clinically, TS follows a waxing and waning course, with symptom severity typically peaking during early adolescence.

The disorder is frequently associated with neurobehavioral comorbidities, particularly attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), significantly increasing disease burden.

Currently, there are no disease-modifying therapies for TS. Treatment is symptom-driven, with Comprehensive Behavioral Intervention for Tics (CBIT) as the first-line approach. Pharmacological therapies-including alpha-2 adrenergic agonists, dopamine antagonists, and VMAT2 inhibitors-are used in moderate-to-severe cases where tics significantly impact quality of life.

Key Highlights

• The TS patient population is predominantly pediatric, with children and adolescents accounting for the majority of diagnosed cases. In the United States, the diagnosed TS population (children and adolescents) is estimated at 159,313 in 2025, increasing to 168,631 by 2035.
• The adult diagnosed population remains significantly smaller, projected to grow from 15,815 in 2025 to 17,008 by 2035, reflecting a strong pediatric skew (~90% of total diagnosed cases).
• Diagnosed TS cases are expected to grow steadily across both pediatric and adult populations over the forecast period.
• Despite increasing diagnosis rates, a significant proportion of patients-particularly those with mild symptoms-remain undiagnosed or untreated, indicating a substantial unmet need.

Market Overview

• The Tourette syndrome treatment market was valued at $2.14 billion in 2025 (8MM) and is projected to reach $2.92 billion by 2035, growing at a CAGR of 4.1%.
• Short-term growth is expected to be stronger (6-7% CAGR through 2030), driven by pipeline advancements and improved treatment uptake.
• The pediatric population contributes the majority of revenue (65%+ share), reflecting higher diagnosis and treatment rates in younger patients.
• Overall, the TS treatment landscape is characterized by steady market expansion, driven by increasing awareness, improved diagnosis, and incremental therapeutic innovation.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Emalex Biosciences Inc.
• Noema Pharma AG
• Neurothera Labs Inc.
• Asarina Pharma